Cytomegalovirus Colitis during Dasatinib Treatment for Patients with Hematologic Malignancy: Case Series and Literature Review
Dasatinib, a tyrosine kinase inhibitor, is widely used for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Although the drug has a potent immunosuppressive effect, infectious complications during dasatinib treatment have been reported rarely....
Saved in:
| Published in | Infection & chemotherapy Vol. 50; no. 2; pp. 153 - 159 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
The Korean Society of Infectious Diseases and Korean Society for Chemotherapy
01.06.2018
대한감염학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2093-2340 2092-6448 |
| DOI | 10.3947/ic.2018.50.2.153 |
Cover
| Abstract | Dasatinib, a tyrosine kinase inhibitor, is widely used for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Although the drug has a potent immunosuppressive effect, infectious complications during dasatinib treatment have been reported rarely. We describe five patients who developed cytomegalovirus (CMV) colitis during dasatinib treatment, in whom the colitis was initially confused with other causes. The patients, three with chronic myeloid leukemia, and two with acute lymphoblastic leukemia, were diagnosed with CMV colitis based on endoscopic and histologic findings. The patients who examined blood CMV polymerase chain reaction were all positive. The patients received antiviral therapy in the form of either ganciclovir or valganciclovir, and the overall treatment outcome was fair. These cases suggest that physicians should consider the possibility of CMV reactivation when treating diarrhea and/or hematochezia in patients on dasatinib. |
|---|---|
| AbstractList | Dasatinib, a tyrosine kinase inhibitor, is widely used for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Although the drug has a potent immunosuppressive effect, infectious complications during dasatinib treatment have been reported rarely. We describe five patients who developed cytomegalovirus (CMV) colitis during dasatinib treatment, in whom the colitis was initially confused with other causes. The patients, three with chronic myeloid leukemia, and two with acute lymphoblastic leukemia, were diagnosed with CMV colitis based on endoscopic and histologic findings. The patients who examined blood CMV polymerase chain reaction were all positive. The patients received antiviral therapy in the form of either ganciclovir or valganciclovir, and the overall treatment outcome was fair. These cases suggest that physicians should consider the possibility of CMV reactivation when treating diarrhea and/or hematochezia in patients on dasatinib. Dasatinib, a tyrosine kinase inhibitor, is widely used for patients with chronic myeloid leukemia and Philadelphia chromosome- positive acute lymphoblastic leukemia. Although the drug has a potent immunosuppressive effect, infectious complications during dasatinib treatment have been reported rarely. We describe five patients who developed cytomegalovirus (CMV) colitis during dasatinib treatment, in whom the colitis was initially confused with other causes. The patients, three with chronic myeloid leukemia, and two with acute lymphoblastic leukemia, were diagnosed with CMV colitis based on endoscopic and histologic findings. The patients who examined blood CMV polymerase chain reaction were all positive. The patients received antiviral therapy in the form of either ganciclovir or valganciclovir, and the overall treatment outcome was fair. These cases suggest that physicians should consider the possibility of CMV reactivation when treating diarrhea and/or hematochezia in patients on dasatinib. KCI Citation Count: 1 Dasatinib, a tyrosine kinase inhibitor, is widely used for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Although the drug has a potent immunosuppressive effect, infectious complications during dasatinib treatment have been reported rarely. We describe five patients who developed cytomegalovirus (CMV) colitis during dasatinib treatment, in whom the colitis was initially confused with other causes. The patients, three with chronic myeloid leukemia, and two with acute lymphoblastic leukemia, were diagnosed with CMV colitis based on endoscopic and histologic findings. The patients who examined blood CMV polymerase chain reaction were all positive. The patients received antiviral therapy in the form of either ganciclovir or valganciclovir, and the overall treatment outcome was fair. These cases suggest that physicians should consider the possibility of CMV reactivation when treating diarrhea and/or hematochezia in patients on dasatinib.Dasatinib, a tyrosine kinase inhibitor, is widely used for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Although the drug has a potent immunosuppressive effect, infectious complications during dasatinib treatment have been reported rarely. We describe five patients who developed cytomegalovirus (CMV) colitis during dasatinib treatment, in whom the colitis was initially confused with other causes. The patients, three with chronic myeloid leukemia, and two with acute lymphoblastic leukemia, were diagnosed with CMV colitis based on endoscopic and histologic findings. The patients who examined blood CMV polymerase chain reaction were all positive. The patients received antiviral therapy in the form of either ganciclovir or valganciclovir, and the overall treatment outcome was fair. These cases suggest that physicians should consider the possibility of CMV reactivation when treating diarrhea and/or hematochezia in patients on dasatinib. |
| Author | Kim, Gyo Hui Kim, Dong-Wook Lee, Seok Choi, Jae-Ki Cho, Sung-Yeon Lee, Sung-Eun Choi, Su-Mi Lee, Dong-Gun |
| AuthorAffiliation | 1 Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea 2 Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea 3 Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea |
| AuthorAffiliation_xml | – name: 2 Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea – name: 1 Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea – name: 3 Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea |
| Author_xml | – sequence: 1 givenname: Jae-Ki orcidid: 0000-0003-4666-960X surname: Choi fullname: Choi, Jae-Ki organization: Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea., Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 2 givenname: Sung-Yeon surname: Cho fullname: Cho, Sung-Yeon organization: Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea., Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea., Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 3 givenname: Su-Mi surname: Choi fullname: Choi, Su-Mi organization: Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea., Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 4 givenname: Gyo Hui surname: Kim fullname: Kim, Gyo Hui organization: Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 5 givenname: Sung-Eun surname: Lee fullname: Lee, Sung-Eun organization: Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 6 givenname: Seok surname: Lee fullname: Lee, Seok organization: Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 7 givenname: Dong-Wook surname: Kim fullname: Kim, Dong-Wook organization: Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 8 givenname: Dong-Gun orcidid: 0000-0003-4655-0641 surname: Lee fullname: Lee, Dong-Gun organization: Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea., Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea., Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29968984$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002362819$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp1Us1v0zAUj9AQG2N3TshHOLTYjp3EHJCm8LFJRaBRztaL63SPJfawnU698LfjthsCJHx5T_bvw8_-PS2OnHe2KJ4zOi-VqF-jmXPKmrmkcz5nsnxUnHCq-KwSojna9-WMl4IeF2cxfqd5NY1gqnpSHHOlqkY14qT42W6TH-0aBr_BMEXS-gETRrKaAro1eQcREjrsyDJYSKN1ifQ-kC95N_eR3GG6Jhd2hOQHv0ZDPsGAawfObN-QFqIlX21AGwm4FVlgsgHSFCy5shu0d8-Kxz0M0Z7d19Pi24f3y_Zitvj88bI9X8yMKGmadR3lBoDZnjHVGNGDULRkvKx723GhKiNrluc1wBuzUlJ1wKSkRoLkslzV5Wnx6qDrQq9vDGoPuK9rr2-CPr9aXmohaloLkbFvD9jbqRvtyuQxAwz6NuAIYbtn_n3i8DrrbHSVrySVygIv7wWC_zHZmPSI0dhhAGf9FDWnVVlTpSTL0Bd_ev02efigDKgOABN8jMH22mDKb-931jhoRvUuDBqN3oVBS6q5zmHIRPoP8UH7v5RfsrK5Fw |
| CitedBy_id | crossref_primary_10_1177_20406207241291736 crossref_primary_10_5223_pghn_2023_26_4_224 crossref_primary_10_1126_sciadv_add1168 crossref_primary_10_1182_bloodadvances_2023011562 crossref_primary_10_1016_j_jfma_2020_10_009 crossref_primary_10_1056_NEJMoa2016272 crossref_primary_10_1128_CMR_00035_19 crossref_primary_10_1136_jclinpath_2022_208340 crossref_primary_10_1080_00365521_2021_2022190 crossref_primary_10_1111_jpc_16749 crossref_primary_10_1136_bcr_2020_239394 crossref_primary_10_17352_ijpsdr_000046 crossref_primary_10_1007_s40278_018_50226_6 crossref_primary_10_1007_s00520_023_08258_5 crossref_primary_10_3390_biology9120455 crossref_primary_10_17235_reed_2020_6789_2019 |
| Cites_doi | 10.1182/blood-2007-04-084814 10.1016/S1386-6532(02)00091-4 10.1200/JCO.2009.25.0779 10.4291/wjgp.v4.i3.59 10.1007/s12185-012-1132-8 10.1093/clinids/22.6.1046 10.3816/CLM.2006.n.016 10.1038/leu.2011.135 10.1182/blood-2007-02-073528 10.1093/clinids/24.1.52 10.3947/ic.2015.47.2.105 10.1093/cid/ciu969 10.1007/s11908-011-0224-6 10.1080/10428190701760086 |
| ContentType | Journal Article |
| Copyright | Copyright © 2018 by The Korean Society of Infectious Diseases and Korean Society for Chemotherapy. Copyright © 2018 by The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2018 The Korean Society of Infectious Diseases and Korean Society for Chemotherapy |
| Copyright_xml | – notice: Copyright © 2018 by The Korean Society of Infectious Diseases and Korean Society for Chemotherapy. – notice: Copyright © 2018 by The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2018 The Korean Society of Infectious Diseases and Korean Society for Chemotherapy |
| DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
| DOI | 10.3947/ic.2018.50.2.153 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2092-6448 |
| EndPage | 159 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_4470744 PMC6031599 29968984 10_3947_ic_2018_50_2_153 |
| Genre | Case Reports |
| GroupedDBID | --- 5-W 8JR 8XY 9ZL AAYXX ABDBF ACUHS ACYCR ADBBV ADRAZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION C~G DIK DYU EBD EF. GROUPED_DOAJ HYE KQ8 M48 M~E OK1 PGMZT RPM NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c430t-bb02caa1ef1198c4fa49031237feb2496c571093ca28cd959ba1550c5a5253d73 |
| IEDL.DBID | M48 |
| ISSN | 2093-2340 |
| IngestDate | Fri May 30 10:58:05 EDT 2025 Thu Aug 21 18:10:52 EDT 2025 Fri Jul 11 06:45:19 EDT 2025 Thu Apr 03 06:58:38 EDT 2025 Thu Apr 24 23:02:15 EDT 2025 Tue Jul 01 03:31:25 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Cytomegalovirus Dasatinib Colitis |
| Language | English |
| License | Copyright © 2018 by The Korean Society of Infectious Diseases and Korean Society for Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c430t-bb02caa1ef1198c4fa49031237feb2496c571093ca28cd959ba1550c5a5253d73 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| ORCID | 0000-0003-4655-0641 0000-0003-4666-960X |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3947/ic.2018.50.2.153 |
| PMID | 29968984 |
| PQID | 2063709951 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_4470744 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6031599 proquest_miscellaneous_2063709951 pubmed_primary_29968984 crossref_citationtrail_10_3947_ic_2018_50_2_153 crossref_primary_10_3947_ic_2018_50_2_153 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-06-01 |
| PublicationDateYYYYMMDD | 2018-06-01 |
| PublicationDate_xml | – month: 06 year: 2018 text: 2018-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Infection & chemotherapy |
| PublicationTitleAlternate | Infect Chemother |
| PublicationYear | 2018 |
| Publisher | The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 대한감염학회 |
| Publisher_xml | – name: The Korean Society of Infectious Diseases and Korean Society for Chemotherapy – name: 대한감염학회 |
| References | Lemonovich (10.3947/ic.2018.50.2.153_ref12) 2012; 14 Torres (10.3947/ic.2018.50.2.153_ref6) 2007; 48 Schade (10.3947/ic.2018.50.2.153_ref1) 2008; 111 Ko (10.3947/ic.2018.50.2.153_ref13) 2015; 60 Torres (10.3947/ic.2018.50.2.153_ref16) 2006; 6 Baccarani (10.3947/ic.2018.50.2.153_ref2) 2009; 27 Ottmann (10.3947/ic.2018.50.2.153_ref3) 2007; 110 de la Hoz (10.3947/ic.2018.50.2.153_ref4) 2002; 25 Chang (10.3947/ic.2018.50.2.153_ref15) 2011; 34 Kreutzman (10.3947/ic.2018.50.2.153_ref7) 2011; 25 Sunami (10.3947/ic.2018.50.2.153_ref9) 2011; 52 Eddleston (10.3947/ic.2018.50.2.153_ref17) 1997; 24 Kim (10.3947/ic.2018.50.2.153_ref11) 2015; 47 Tanaka (10.3947/ic.2018.50.2.153_ref14) 2012; 96 Yassin (10.3947/ic.2018.50.2.153_ref8) 2015; 8 Mera (10.3947/ic.2018.50.2.153_ref10) 1996; 22 Kmira (10.3947/ic.2018.50.2.153_ref5) 2013; 4 |
| References_xml | – volume: 52 start-page: 282 year: 2011 ident: 10.3947/ic.2018.50.2.153_ref9 publication-title: Rinsho Ketsueki – volume: 111 start-page: 1366 year: 2008 ident: 10.3947/ic.2018.50.2.153_ref1 publication-title: Blood doi: 10.1182/blood-2007-04-084814 – volume: 25 start-page: S1 issue: Suppl 2 year: 2002 ident: 10.3947/ic.2018.50.2.153_ref4 publication-title: J Clin Virol doi: 10.1016/S1386-6532(02)00091-4 – volume: 27 start-page: 6041 year: 2009 ident: 10.3947/ic.2018.50.2.153_ref2 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.25.0779 – volume: 4 start-page: 59 year: 2013 ident: 10.3947/ic.2018.50.2.153_ref5 publication-title: World J Gastrointest Pathophysiol doi: 10.4291/wjgp.v4.i3.59 – volume: 96 start-page: 308 year: 2012 ident: 10.3947/ic.2018.50.2.153_ref14 publication-title: Int J Hematol doi: 10.1007/s12185-012-1132-8 – volume: 8 start-page: 77 year: 2015 ident: 10.3947/ic.2018.50.2.153_ref8 publication-title: Clin Med Insights Case Rep – volume: 22 start-page: 1046 year: 1996 ident: 10.3947/ic.2018.50.2.153_ref10 publication-title: Clin Infect Dis doi: 10.1093/clinids/22.6.1046 – volume: 6 start-page: 393 year: 2006 ident: 10.3947/ic.2018.50.2.153_ref16 publication-title: Clin Lymphoma Myeloma doi: 10.3816/CLM.2006.n.016 – volume: 25 start-page: 1587 year: 2011 ident: 10.3947/ic.2018.50.2.153_ref7 publication-title: Leukemia doi: 10.1038/leu.2011.135 – volume: 110 start-page: 2309 year: 2007 ident: 10.3947/ic.2018.50.2.153_ref3 publication-title: Blood doi: 10.1182/blood-2007-02-073528 – volume: 34 start-page: 65 year: 2011 ident: 10.3947/ic.2018.50.2.153_ref15 publication-title: Chang Gung Med J – volume: 24 start-page: 52 year: 1997 ident: 10.3947/ic.2018.50.2.153_ref17 publication-title: Clin Infect Dis doi: 10.1093/clinids/24.1.52 – volume: 47 start-page: 105 year: 2015 ident: 10.3947/ic.2018.50.2.153_ref11 publication-title: Infect Chemother doi: 10.3947/ic.2015.47.2.105 – volume: 60 start-page: e20 year: 2015 ident: 10.3947/ic.2018.50.2.153_ref13 publication-title: Clin Infect Dis doi: 10.1093/cid/ciu969 – volume: 14 start-page: 33 year: 2012 ident: 10.3947/ic.2018.50.2.153_ref12 publication-title: Curr Infect Dis Rep doi: 10.1007/s11908-011-0224-6 – volume: 48 start-page: 2308 year: 2007 ident: 10.3947/ic.2018.50.2.153_ref6 publication-title: Leuk Lymphoma doi: 10.1080/10428190701760086 |
| SSID | ssj0000884196 |
| Score | 2.1677175 |
| Snippet | Dasatinib, a tyrosine kinase inhibitor, is widely used for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic... Dasatinib, a tyrosine kinase inhibitor, is widely used for patients with chronic myeloid leukemia and Philadelphia chromosome- positive acute lymphoblastic... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 153 |
| SubjectTerms | Case Report 내과학 |
| Title | Cytomegalovirus Colitis during Dasatinib Treatment for Patients with Hematologic Malignancy: Case Series and Literature Review |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29968984 https://www.proquest.com/docview/2063709951 https://pubmed.ncbi.nlm.nih.gov/PMC6031599 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002362819 |
| Volume | 50 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Infection and Chemotherapy, 2018, 50(2), , pp.153-159 |
| journalDatabaseRights | – providerCode: PRVCAB databaseName: Nutrition and Food Sciences Database customDbUrl: eissn: 2092-6448 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884196 issn: 2093-2340 databaseCode: DYU dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.cabidigitallibrary.org/product/zd providerName: CAB International – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2092-6448 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884196 issn: 2093-2340 databaseCode: KQ8 dateStart: 20130101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2092-6448 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884196 issn: 2093-2340 databaseCode: DOA dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 2092-6448 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884196 issn: 2093-2340 databaseCode: ABDBF dateStart: 20120801 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2092-6448 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884196 issn: 2093-2340 databaseCode: DIK dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2092-6448 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884196 issn: 2093-2340 databaseCode: M~E dateStart: 20090101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVERR databaseName: KoreaMed Open Access customDbUrl: eissn: 2092-6448 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884196 issn: 2093-2340 databaseCode: 5-W dateStart: 20100101 isFulltext: true titleUrlDefault: https://koreamed.org/journals providerName: Korean Association of Medical Journal Editors – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2092-6448 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000884196 issn: 2093-2340 databaseCode: RPM dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2092-6448 dateEnd: 20250630 omitProxy: true ssIdentifier: ssj0000884196 issn: 2093-2340 databaseCode: M48 dateStart: 20130301 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Pb9MwFLbYuHBBIH6FwWQQFw7pEseO7UkIocJUEEUcVmmcLNtxR7QtgaSd6IW_nfeStFBUuCSHOI6S55f3ffbz9wh5EZjKi6Bc7G3CUVQ7R58LsS9S6b10znZlOqef8smMfzgTZ7-3Rw8fsN1J7bCe1Ky5HP34vnoNDv8KGafm8qhEKcJUjUQyYiPw4D1yE-ISwzE-HcB-919WiqddwS4GND5mGU_6dcudnaBKMHABpRXfCll7VTPfhUb_Tqr8I0qd3CG3B3hJ3_Tj4S65Eap75Od4taivAsSC-rpsli0dd0lvLe33KNK3FlN6qtLR03XaOQUsSz_3mqstxclaOkF11_5XSaeA3s9RqmN1TMcQBylOsoWW2qqgHzdCzbRfeLhPZifvTseTeKi7EHueJYvYuYR5a9MwT1OtPJ9brsH3WSbnwMO5zr3ADM7MW6Z8oYV2FomOF1YwkRUye0D2q7oKj3BHuOTQJgBtcVxqZYusyB2gHofSf0WIyNH60xo_iJJjbYxLA-QE7WJKb9AuRiSGGbBLRF5u7vjWC3L8p-1zsJa58KVBFW08n9fmojHAFd4bziXgJx6RZ2tjGnAtXC-xVaiXLfSVZxIQtEgj8rA37uaR67EREbll9k0DfOD2lar82sl3Y11vofXjf_Z5QG7ha_QJaU_I_qJZhqcAfRbusJsywOOX2WE3un8BnH8CSQ |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cytomegalovirus+Colitis+during+Dasatinib+Treatment+for+Patients+with+Hematologic+Malignancy%3A+Case+Series+and+Literature+Review&rft.jtitle=Infection+%26+chemotherapy&rft.au=Choi%2C+Jae+Ki&rft.au=Cho%2C+Sung+Yeon&rft.au=Choi%2C+Su+Mi&rft.au=Kim%2C+Gyo+Hui&rft.date=2018-06-01&rft.issn=2093-2340&rft.volume=50&rft.issue=2&rft.spage=153&rft_id=info:doi/10.3947%2Fic.2018.50.2.153&rft_id=info%3Apmid%2F29968984&rft.externalDocID=29968984 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2093-2340&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2093-2340&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2093-2340&client=summon |